Enveda Biosciences raised $311 million in a Series E to fund advancement of an AI-driven pipeline with three oral candidates in human testing. The Nature-derived and microbe-derived chemistry approach is now moving beyond early validation, with Phase 2 and Phase 1 programs focused on atopic dermatitis, obesity and inflammatory bowel disease. The funding round was led by Catalio Capital Management, with participation from Surveyor Capital, T. Rowe Price, Lux Capital and a sovereign wealth fund. Enveda said it will use the capital to scale its platform while expanding development capabilities for later-stage programs. Separately, Basecamp Research secured an oversubscribed $140 million Series C supported by Anthropic via its Anthology Fund and other investors. The company plans to train next-generation EDEN models aimed at improving in vivo cell therapies across oncology and autoimmune disease, reflecting sustained investor demand for AI-native therapeutic design.